Skip to main content.
Home / ETF / Virtus LifeSci Biotech Products ETF

Virtus LifeSci Biotech Products ETF

Image specific to each asset class and market style grouping.
Ticker
BBP
CUSIP
26923G202
Closing Price
$
(as of 11/16/2017)
Inception
12/16/2014
Premium/Discount
$0.61
(as of 11/16/2017)
4PM Bid/Offer Midpoint
$39.34
(as of 11/16/2017)
Shares Outstanding
950,004
(as of 11/16/2017)
Daily Trading Volume
3,135.00
(as of 11/16/2017)
20 Day Average Trading Volume
5,493.00
(as of 11/16/2017)
Net Assets
$36,796,368
(as of 11/16/2017)
Product Overview

Biotechnology investors have the opportunity to gain exposure to one of the most exciting, high-growth sectors in the global economy today. These companies are in the business of designing drugs that save lives. Everything ranging from antivirals, antibiotics and cancer-fighting medicines to gene therapies, cell-based therapies and enzyme replacement therapies are developed in the biotech sector. The Fund invests in products stage companies, which are typically more established companies with much clinical trial failure risk behind them. They have already successfully completed multiple human clinical trials and have received FDA approval to sell and market a drug. They devote more of their energies toward educating patients, physicians and insurance providers in order to drive sales and profit growth. The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index.

Management Team

Investment Partners

LifeSci Index Partners, LLC

LifeSci Index Partners, LLC is a New York-based index provider of healthcare-based stock market indices. The LifeSci team is comprised of investment professionals with experience in biotechnology equity research, in organic chemistry research in academia, and at pharmaceutical and biotechnology companies.

Portfolio Managers
Matthew Brown
Matthew B. Brown

Executive Managing Director and Chief Operating Officer

Industry start date: 1999

Show More
Seth Kadushin
Seth Kadushin

Director of Capital Markets

Industry start date: 1988

Show More

Positions & Distributions

Positions
(as of 11/17/2017)
Security % of Portfolio
NEKTAR THERAPEUTICS
6.51
SAREPTA THERAPEUTICS INC
4.44
NEUROCRINE BIOSCIENCES INC
4.40
ENANTA PHARMACEUTICALS INC
4.00
HALOZYME THERAPEUTICS INC
3.74
EXELIXIS INC
3.51
BIOGEN INC
3.31
LIGAND PHARMACEUTICALS
3.27
RETROPHIN INC
3.17
VERTEX PHARMACEUTICALS INC
3.17

Performance & Risk

Performance
Quarterly
As of
Monthly
As of
1 Month 3 Month YTD 1 Year 3 Years 5 Years 10 Years Since Inception

Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate, so your shares, when redeemed, may be worth more or less than their original cost.

Sales Charge and Expenses
The Gross Expense Ratio represents the fund's management fee, which is structured as a unified fee, out of which the Fund's adviser pays all routine expenses, except for certain payments as described in the prospectus, which are paid by the Fund.
Fees & Expenses
Gross Expense Ratio 0.79
The Gross Expense Ratio represents the fund's management fee, which is structured as a unified fee, out of which the Fund's adviser pays all routine expenses, except for certain payments as described in the prospectus, which are paid by the Fund.
Premium/Discount
Number of Days Fund has Traded at a:
Discount Premium
Period Less than -2% -1.51% to -2.00% -1.01% to -1.50% -0.51% to -1.00% -0.01% to -0.50% 0.00% to 0.50% 0.51% to 1.00% 1.01% to 1.50% 1.51% to 2.00% Greater than 2%
2014-Q4: 12/16/2014 through 12/31/2014 0 0 0 0 3 8 0 0 0 0
2015-Q1: 1/2/2015 through 3/31/2015 0 0 0 0 28 33 0 0 0 0
2015-Q2: 4/1/2015 through 6/30/2015 0 0 0 1 23 38 1 0 0 0
2015-Q3: 7/1/2015 through 9/30/2015 0 0 0 0 28 36 0 0 0 0
2015-Q4: 10/1/2015 through 12/31/2015 0 0 0 0 36 27 0 1 0 0
2016-Q1: 1/4/2016 through 3/31/2016 0 0 0 0 36 25 0 0 0 0
2016-Q2: 4/1/2016 through 6/30/2016 0 0 0 0 27 37 0 0 0 0
2016-Q3: 7/1/2016 through 9/30/2016 0 0 0 0 19 45 0 0 0 0
2016-Q4: 10/3/2016 through 12/30/2016 0 0 0 0 28 35 0 0 0 0
2017-Q1: 1/3/2017 through 3/31/2017 0 0 0 0 30 32 0 0 0 0
2017-Q2: 4/3/2017 through 6/30/2017 0 0 0 0 35 28 0 0 0 0
2017-Q3: 7/3/2017 through 9/29/2017 0 0 0 0 50 13 0 0 0 0
Risk Considerations
Exchange Traded Funds: The value of an ETF may be more volatile than the underlying portfolio of securities the ETF is designed to track. The costs of owning the ETF may exceed the cost of investing directly in the underlying securities.
Industry/Sector Concentration: A fund that focuses its investments in a particular industry or sector will be more sensitive to conditions that affect that industry or sector than a non-concentrated fund.
Market Price/NAV: At the time of purchase and/or sale, an investor's shares may have a market price that is above or below the fund's NAV, which may increase the investor's risk of loss.
Correlation to Index: The performance of the fund and its index may vary somewhat due to factors such as fund flows, transaction costs, and timing differences associated with additions to and deletions from its index.
Non-Diversified: The fund is non-diversified and may be more susceptible to factors negatively impacting its holdings to the extent that each security represents a larger portion of the fund's assets.
No Guarantee: There is no guarantee that the portfolio will meet its objective.
Prospectus: For additional information on risks, please see the fund's prospectus.

Documents & Resources

Marketing Materials
LifeSci Biotech Products ETF Fact Sheet (BBP)
Holdings
Positions ETF-BBP
Financial Materials
ETFis Series Trust I - Prospectus Supplement - October 5, 2017
BBP and BBC Prospectus Supplement
BBP and BBC - Prospectus
XBRL - BioShares Biotechnology ETFs (BBP, BBC)
ETFis Series Trust I - SAI Supplement - October 5, 2017
BBP and BBC Prospectus Supplement
BBP and BBC - SAI
ETFis Series Trust I Annual Report
ETFis Series Trust I Semi-Annual Report
News
Virtus ETF Announces Changes to LifeSci Biotech ETFs (BBC, BBP)

Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. The prospectus contains this and other information about the Fund. Contact us at 1-888-383-0553 or visit www.virtus.com for a copy of the Fund's prospectus. Read the prospectus carefully before you invest or send money.

Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate so your shares, when redeemed, may be worth more or less than their original cost.

Closing Price:
 The Closing Price is the price of the last reported trade on the fund's primary exchange. If there has been no reported trade for a particular date, the Closing Price represents the 4PM Bid/Offer Midpoint. 

4PM Bid/Offer Midpoint: The midpoint between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00pm Eastern Time).

Premium/Discount: The amount the Fund is trading above or below the reported NAV (based on 4PM Bid/Offer Midpoint).

The Fund is an exchange-traded fund (“ETF”). The “net asset value” (NAV) of the Fund is determined at the close of each business day, and represents the dollar value of one share of the Fund; it is calculated by taking the total assets of the Fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV of the Fund is not necessarily the same as its intraday trading value. Fund investors should not expect to buy or sell shares at NAV because shares of ETFs such as the Fund are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Thus, shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.

NAV returns are calculated using the Fund’s daily 4:00 p.m. NAV, and include the reinvestment of all dividends and other distributions (reinvested at the Fund's NAV on distribution ex-date). Market price returns are calculated using the 4:00 pm midpoint between the bid and offer, and include the reinvestment of all dividends and other distributions (reinvested at the 4:00pm bid/offer midpoint on distribution ex-date). Market price returns do not represent the return you would receive if you traded at other times.

SEC Yield is an annualized yield that is calculated by dividing the investment income earned by the Fund less expenses over the most recent 30 day period by the current NAV at the end of the 30 day period. The Subsidized Yield reflects fee waivers and/or expense reimbursements recorded by the Fund during the period. Without waivers and/or reimbursements, yields would be reduced. The Unsubsidized Yield does not adjust for any fee waivers and/ or expense reimbursements in effect. If the Fund does not incur any fee waivers and/or expense reimbursements during the period, the Subsidized Yield and Unsubsidized Yield will be identical.

Distribution Yield is the annual yield that an investor would receive if the most recent distribution remained the same going forward. The yield represents a single distribution from the Fund and does not represent total return of the Fund. The distribution yield is calculated by annualizing the most recent distribution and dividing it by the most recent NAV.

Returns for periods of less than one year are cumulative total returns.

Not insured by FDIC/NCUSIF or any federal government agency. No bank guarantee. Not a deposit. May lose value.

Distributed by ETF Distributors LLC